latest news releases from the newsroom
MEDTOX Scientific, Inc.
MEDTOX Scientific Announces Second Quarter Conference Call
ST. PAUL, Minn., July 9, 2008 (PRIME NEWSWIRE) -- MEDTOX Scientific, Inc. (Nasdaq:MTOX), announced today that it will hold a teleconference to discuss second quarter results on Wednesday, July 16, at 9:30 a.m. Central Time (10:30 a.m. Eastern). During the conference call, the Company may discuss and answer questions concerning business and financial developments and trends. The Company's responses to questions, as well as other matters discussed during the conference call, may contain or constitute information that has not been disclosed previously. MEDTOX is scheduled to release financial results for the quarter at approximately 6:00 a.m. Central Time on July 16.
SoundBite Communications, Inc.
Mercator Advisory Group and SoundBite Communications to Host Webinar Designed to Help Card Issuers Improve Cardholder Response With Multi-Channel Communications
BEDFORD, Mass., July 9, 2008 (PRIME NEWSWIRE) -- Card issuers face intense competition to make their card the top-of-wallet choice among consumers while optimizing collections results at the same time. In order to overcome these dual challenges, card issuers are seeking to implement best practices in proactive customer communications strategies that align with the changing communications landscape of today's highly mobile consumer. Card issuers are requesting customer communication solutions that can scale across the entire cardholder lifecycle -- including origination, activation, loyalty and reward program participation, and collections.
Generex Biotechnology Corp.
Investigational New Drug Application Submitted On Behalf of Generex Biotechnology for Combination Immunotherapy Vaccine Trials
WORCESTER, Mass., July 9, 2008 (PRIME NEWSWIRE) -- An Investigational New Drug application (IND) has been submitted to the United States Food and Drug Administration (FDA) on behalf of Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) for its AE37 immunotherapeutic vaccine combined with a vaccine peptide that works by a different mechanism for patients. The immunotherapeutic cancer vaccine AE37 is being developed through Antigen Express, Inc. (www.antigenexpress.com), the wholly owned immunotherapeutics subsidiary of Generex.
Transocean Inc. Provides Fleet Status Report
HOUSTON, July 9, 2008 (PRIME NEWSWIRE) -- Transocean Inc. (NYSE:RIG) today issued an updated fleet status report covering the company's 137-unit offshore drilling fleet.